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Cases of fluconazole-resistant Cryptococcus neoformans have been reported in AIDS
patients previously treated with fluconazole. We report a case of fluconazole-resistant
cryptococcal meningitis in an HIV-negative patient not previously exposed to flucona-
zole. The patient experienced a clinical relapse after discontinuation of therapy with
amphotericin B and subsequent initiation of fluconazole therapy. In vitro resistance was
initially verified by Etest and tablet diffusion and later confirmed by NCCLS broth
microdilution.
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C A S E R E P O R T
A 66-year-old-man with chronic lymphocytic leu-
kemia (CLL), diagnosed 2 years earlier, presented
with general weakness, headache, vertigo, and
diplopia. The patient was treated for CLL with
15 mg/day of prednisolone in combination with
chlorambucil, 4 mg/day. The patient had no recol-
lection of exposure to bird feces, had never been
outside Europe, and had not received fluconazole
therapy. Three months previously, the patient had
been admitted to a nearby hospital, due to general
malaise and confusion. Examination of cerebrosp-
inal fluid (CSF) revealed mononuclear pleocytosis
(Table 1) and negative herpesvirus polymerase
chain reaction (PCR). Intravenous penicillin and
aciclovir were administered for 1 week. After
release, the patient still had neurologic complaints.
At the time of the current admission, the patient
was afebrile with no focal neurologic deficits.
Paraclinical findings following admission were
as follows: hemoglobin 10.9 g/dL; white count
52 700/mm3, with 2% neutrophils and 91% lym-
phocytes; normal C-reactive protein; IgA<0.3 g/L
(0.7–4.3 g/L); IgG 2.8 g/L (6.1–14.9 g/L); IgM
<0.4 g/L (0.39–2.08 g/L). An X-ray showed bilat-
eral pulmonary infiltrates. A combination of
intravenous cefuroxime (750 mg every 8 h) and
intravenous ciprofloxacin (400 mg every 12 h)
was given for 8 days, followed by intravenous
meropenem (1 g every 8 h) administered for
14 days. HIV (serotypes 1 and 2) serology was
negative. On day 8, headache, vertigo and nausea
persisted. CSF examination showed mononuclear
pleocytosis (Table 1). Wet mount microscopy of
the CSF with India ink demonstrated yeast-like
fungi. Therapy was initiated with intravenous am-
photericin B, 50 mg/day (0.7–1.0 mg/kg/day).
Supplementary therapy with flucytosine was not
given, since flucytosine had been withdrawn from
the Danish market. Additional therapy with intra-
venous fluconazole, 400 mg/day was given initi-
ally for 8 days. After 1 week of antifungal
treatment (2 weeks after admission), the neurolo-
gic symptoms had disappeared. CSF examination
showed pleocytosis, and no signs of fungi
(Table 1). On day 39, treatment with amphotericin
B was discontinued. Maintenance therapy with
fluconazole, 400 mg/day orally was initiated. On
day 44, signs of confusion and mental impairment
reappeared. A new lumbar puncture (6 weeks
after admission) revealed a moderate pleocytosis
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and decreased glucose CSF/blood ratio, but no
fungi were found (Table 1). Treatment with fluco-
nazole was terminated, and intravenous ampho-
tericin B therapy, 50 mg/day was resumed. After 7
weeks of antifungal therapy (6 weeks with ampho-
tericin B, 1 week with fluconazole), treatment with
amphotericin B was discontinued, due to impaired
renal function. The patient was discharged, afeb-
rile, with a total absence of the initial neurologic
manifestations. Six months later, the patient exhib-
ited mental manifestations indicating relapse of
infection. CSF examination revealed a decreased
glucose level, an increased protein level, mono-
nuclear pleocytosis, and presence of cryptococcal
antigen (titer 1 : 8, latex agglutination). Treatment
with liposomal amphotericin B was initiated, lead-
ing to a rapid improvement in the patient’s mental
condition.
The spinal fluid was concentrated by centrifu-
gation (3000 rev/min for 10 min), and the pellet
was used for microscopy and inoculation of brain–
heart infusion (BHI) medium, Danish blood agar
plates (5%), and chocolate agar plates (SSI Diag-
nostica, Denmark). Cultures were incubated at
35 8C, the agar media in a CO2-supplemented
atmosphere. Using ATB 32C (Bio Merieux,













Leukocyte count (3 106/L) 125 530 203 95 409
Granulocytes (%) 7 0 ND ND 16
Erythrocytes (<1 106/L 6490 31 7 4715 0
Protein (0.15–0.50 g/L) 2.08 1.4 1.43 2.6 3.00
Glucose (2.2–3.9 mM) 3.3 1.1 6.5 5.3 1.6
Microscopya and culturea Negative Positive Negative Negative Negative
CSF/blood glucose ratio 0.49 0.13 ND 0.46 0.26
Blood
Blood glucose (3.5–5 mM) 6.7 8.5 ND 11.4 6.1
aNegative/positive for C. neoformans.
ND, not determined.
Figure 1 Etest susceptibility testing
of fluconazole and amphotericin B.
Susceptibility testing was performed
according to the manufacturer’s re-
commendations. The isolate was
regarded as fluconazole resistant.
The Etest endpoint of amphotericin
B was 0.25 mg/L.
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Marcy-l’Etoile, France) and the formation of
brown pigmented colonies on BCE agar (Brown
color effect plates, SSI Diagnostica, Denmark), the
spinal fluid isolate was identified as Cryptococcus
neoformans var. neoformans. Initial susceptibility
testing by tablet (Rosco, Taastrup, Denmark)
and Etest diffusion (AB Biodisk, Solna, Sweden)
showed the isolate to be amphotericin B suscep-
tible but fluconazole resistant (Figure 1). This was
subsequently confirmed by broth microdilution
according to the National Committee for
Clinical Laboratory Standards [2] (amphotericin
B MIIC 1 mg/L, and fluconazole MIC 32 mg/L)
(Figure 2).
D I S C U S S I O N
C. neoformans var. neoformans primarily affects
immunocompromised patients. In Denmark, the
incidence of cryptococcal meningitis has been low,
i.e. around five cases per year since 1988 [1]. As in
the USA, the majority of cases are observed among
AIDS patients (86%) [1]. Decreased fluconazole
susceptibility among C. neoformans isolates is unu-
sual in HIV-negative patients [3,4]. Thus, flucona-
zole resistance was not demonstrated among 38 C.
neoformans isolates obtained from neutropenic
HIV-negative patients during the period 1986–97
[4]. A few cases of fluconazole-resistant C. neofor-
mans have been described in HIV-positive patients
previously treated with fluconazole [5–7]. How-
ever, two cases of fluconazole-resistant C. neofor-
mans, isolated from two immunocompetent non-
AIDS Israeli patients with no previous fluconazole
exposure, have recently been reported [8,9].
As far as we know, the case described here is the
second case of cryptococcal meningitis with in
vivo and in vitro resistance to fluconazole in an
HIV-negative patient suffering from CLL, with no
previous exposure to fluconazole. The patient was
prone to infection due to the underlying cellular
and humoral immunodeficiency associated with
his CLL and prednisolone therapy. In agreement
with international recommendations [10], our
patient was treated, for a total of almost 6 weeks,
with amphotericin B. Following induction therapy
with amphotericin B, and until fluconazole resis-
tance was firmly established, maintenance therapy
with fluconazole, 400 mg/day orally was pre-
scribed, since in vivo resistance to fluconazole
had not then been described in Denmark. How-
ever, the patient experienced his first clinical
relapse 5 days after the shift to fluconazole and
amphotericin B was resumed, leading to a rapid
improvement in his condition. The two clinical
relapses were not substantiated by positive culture
of the CSF, but the rapid response to amphotericin
B treatment and the CSF findings, with a reduced
CSF/plasma glucose ratio, elevated spinal protein,
and detection of cryptococcal antigen at the second
relapse, were strongly suggestive of a fungal infec-
tion. In conclusion, this case stresses the impor-
tance of susceptibility testing of C. neoformans
isolates in all cases of meningeal cryptococcosis,
even without previous fluconazole exposure.
Furthermore, we were able to demonstrate the
credibility of different susceptibility tests, in rela-
tion to the choice of antifungal therapy.
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